Back to top
more

Atossa Genetics (ATOS)

(Delayed Data from NSDQ)

$0.79 USD

0.79
899,749

-0.02 (-2.14%)

Updated Aug 6, 2025 04:00 PM ET

After-Market: $0.78 -0.01 (-0.99%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth A Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (148 out of 246)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Are Medical Stocks Lagging Atossa Genetics (ATOS) This Year?

by Zacks Equity Research

Here is how Atossa Genetics Inc. (ATOS) and Clover Health Investments, Corp. (CLOV) have performed compared to their sector so far this year.

Zacks Equity Research

All You Need to Know About Atossa Genetics (ATOS) Rating Upgrade to Buy

by Zacks Equity Research

Atossa Genetics (ATOS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Indrajit Bandyopadhyay headshot

TCMD Stock Rises 20% in Three Months: Should You Buy, Hold or Sell?

by Indrajit Bandyopadhyay

Tactile Systems' top line reflects strong demand for its existing products. Workflow enhancements are driving efficiency. Rising Medicare documentation requirements are a headwind.

Zacks Equity Research

Is Atossa Genetics (ATOS) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Atossa Genetics Inc. (ATOS) and Gilead Sciences (GILD) have performed compared to their sector so far this year.

Zacks Equity Research

Is Intuitive Surgical (ISRG) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Intuitive Surgical, Inc. (ISRG) and Atossa Genetics Inc. (ATOS) have performed compared to their sector so far this year.

Zacks Equity Research

Are Medical Stocks Lagging Atossa Genetics (ATOS) This Year?

by Zacks Equity Research

Here is how Atossa Genetics Inc. (ATOS) and Cardinal Health (CAH) have performed compared to their sector so far this year.

Zacks Equity Research

Is Atossa Genetics (ATOS) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Atossa Genetics Inc. (ATOS) and CorMedix (CRMD) have performed compared to their sector so far this year.

Zacks Equity Research

Is Atossa Genetics (ATOS) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Atossa Genetics Inc. (ATOS) and DiaMedica Therapeutics, Inc. (DMAC) have performed compared to their sector so far this year.

Zacks Equity Research

Are You Looking for a Top Momentum Pick? Why Atossa Genetics Inc. (ATOS) is a Great Choice

by Zacks Equity Research

Does Atossa Genetics Inc. (ATOS) have what it takes to be a top stock pick for momentum investors? Let's find out.

Zacks Equity Research

Are Medical Stocks Lagging Atossa Genetics (ATOS) This Year?

by Zacks Equity Research

Here is how Atossa Genetics Inc. (ATOS) and Hologic (HOLX) have performed compared to their sector so far this year.

Zacks Equity Research

Are Medical Stocks Lagging Alvotech (ALVO) This Year?

by Zacks Equity Research

Here is how Alvotech (ALVO) and Atossa Genetics Inc. (ATOS) have performed compared to their sector so far this year.

Zacks Equity Research

Is Atossa Genetics (ATOS) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Atossa Genetics Inc. (ATOS) and Ocugen (OCGN) have performed compared to their sector so far this year.

Zacks Equity Research

Atossa Genetics Inc. (ATOS) is a Great Momentum Stock: Should You Buy?

by Zacks Equity Research

Does Atossa Genetics Inc. (ATOS) have what it takes to be a top stock pick for momentum investors? Let's find out.

Zacks Equity Research

Atossa (ATOS) Reports Positive Results From EVANGELINE Study

by Zacks Equity Research

Atossa (ATOS) unveils positive results from its phase 2 EVANGELINE clinical study, which shows that (Z)-endoxifen can reduce the growth of ER+ breast cancer.

Zacks Equity Research

Is Atossa Genetics (ATOS) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Atossa Genetics Inc. (ATOS) and Amphastar Pharmaceuticals (AMPH) have performed compared to their sector so far this year.